GSK PLC Sponsored ADR (NYSE:GSK) Receives $53.00 Average PT from Analysts

GSK PLC Sponsored ADR (NYSE:GSK) has received a consensus recommendation of “Hold” from the ten brokerages that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, six have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $53.00.

GSK has been the topic of several analyst reports. HSBC upgraded shares of GSK from a “reduce” rating to a “hold” rating in a research note on Monday, July 6th. Wall Street Zen cut GSK from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Citigroup started coverage on GSK in a research report on Friday, July 24th. They set a “neutral” rating on the stock. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of GSK in a report on Thursday, July 30th. Finally, Weiss Ratings cut GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, July 29th.

GSK Stock Performance

Shares of NYSE GSK opened at $50.27 on Thursday. The firm has a 50 day moving average of $51.91 and a 200 day moving average of $53.65. The company has a current ratio of 0.82, a quick ratio of 0.52 and a debt-to-equity ratio of 0.81. The firm has a market capitalization of $101.68 billion, a price-to-earnings ratio of 15.72, a price-to-earnings-growth ratio of 2.92 and a beta of 0.36. GSK has a 12-month low of $38.62 and a 12-month high of $61.69.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 8th. Investors of record on Friday, August 14th will be paid a dividend of $0.4515 per share. This is a boost from GSK’s previous quarterly dividend of $0.44. The ex-dividend date is Friday, August 14th. This represents a $1.81 dividend on an annualized basis and a dividend yield of 3.6%. GSK’s dividend payout ratio is presently 55.94%.

Institutional Investors Weigh In On GSK

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GSK. Brighton Jones LLC bought a new position in shares of GSK in the fourth quarter worth approximately $528,000. Prime Capital Investment Advisors LLC increased its stake in shares of GSK by 182.7% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 30,188 shares of the pharmaceutical company’s stock worth $1,480,000 after purchasing an additional 19,509 shares in the last quarter. Farther Finance Advisors LLC raised its position in shares of GSK by 146.6% during the 4th quarter. Farther Finance Advisors LLC now owns 29,529 shares of the pharmaceutical company’s stock valued at $1,448,000 after purchasing an additional 17,553 shares during the period. Dorsey Wright & Associates bought a new stake in shares of GSK during the 1st quarter valued at $2,522,000. Finally, PFA Pension Forsikringsaktieselskab purchased a new position in shares of GSK during the 4th quarter valued at $6,385,000. Institutional investors own 15.74% of the company’s stock.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.